Recent SEC filings
Insider and ownership filing tracker
Form 4 reports insider transactions. Schedule 13D and 13G filings report certain significant ownership positions. 13F reports institutional holdings when filed by an investment manager. Always open the original filing for context.
Company and financial overview
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
Financial performance charts
Annual values from SEC filings. Free cash flow is calculated as operating cash flow less capital expenditures.
Upcoming catalyst timeline
Review the Earnings tab for the expected date and estimates.
FORM 4
EMA, RSI, MACD, volume, structure, and key levels update after a completed daily candle.
How the research score works
The overall score is a weighted research judgment covering business quality, fundamental strength, growth catalysts, valuation, technical condition, and downside risk. A high score does not eliminate risk, and a low score does not guarantee poor performance.
Company overview
Gilead Sciences is a biopharmaceutical company best known for its dominant position in HIV treatment and prevention, with an expanding oncology portfolio and other therapeutic areas supplementing its core franchise.
Business model
Gilead earns the majority of its revenue from HIV treatment and prevention drugs, which carry high margins and strong physician loyalty, supplemented by a growing oncology business acquired through recent acquisitions.
Growth drivers
- Long acting HIV treatment and prevention drug adoption
- Oncology pipeline and acquired asset growth
- International HIV treatment expansion
- Liver disease and inflammation pipeline progress
Competitive position
Gilead's decades long leadership in HIV treatment, including next generation long acting therapies, gives it a dominant position in that category with high switching costs and strong prescriber relationships.
Risks
Heavy revenue concentration in HIV treatment creates single category risk, oncology acquisitions carry integration and pipeline execution risk, and generic competition eventually affects legacy HIV products as they age.
Valuation
Gilead trades at a discount to some biotech peers given its slower growth profile, with the market watching closely for signs that oncology diversification can offset any future HIV franchise maturation.
Final view
Gilead's HIV franchise remains a durable, high margin business, with oncology diversification offering a path to reduce concentration risk over time. My view is balanced, with oncology pipeline execution being the key catalyst to watch.
Overall rating: 69/100
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market data is provided by Finnhub and other third-party sources and may be delayed, incomplete, or inaccurate. The author may hold positions in securities discussed, and opinions may change without notice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.